Malignant Pleural Mesothelioma (MPM) is a rare but highly lethal tumor with
limited therapeutic options. Patients with
MPM have a poor prognosis, with estimated 1 year median survival and rare cure.
The BRCA associated protein 1 (BAP1) has the highest prevalence of
protein-altering mutations identified in MPM. Platinum based chemotherapy is
one of the first line therapies for MPM. It works on tumor cells by induction
of DNA Double-strand breaks.
Assessment of the effect of BAP1 gene mutations on platinum-induced DNA
Double-strand breaks (DSBs) in Egyptian patients with malignant Pleural
A prospective, cohort study was conducted on patients who were diagnosed and
treated as advanced MPM. BAP1 gene
mutations were assessed from circulating tumor cells (CTCs) in the blood by
polymerase chain reaction (PCR) and sequencing. The relationship between BAP1
gene mutations, and clinical response to platinum based chemotherapy was
assessed using chi-square test.
From the 122 patients assessed, 47 (38.5%) MPM cases showed one or more
mutations in BAP1 gene. No statistically significant difference was found
between patients with or without BAP1 gene mutation and the overall clinical
benefit after Platinum based chemotherapy.
BAP1 gene mutations are relatively common in Egyptian patients. BAP1 mutations
don’t affect the sensitivity of MPM tumor cells to the effect of
platinum-induced Double-strand breaks (DSBs).
Indian Member 40.00
Others Member 3.00